Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Total Current Liabilities (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Total Current Liabilities for 6 consecutive years, with $6.7 million as the latest value for Q3 2025.

  • Quarterly Total Current Liabilities rose 36.45% to $6.7 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $6.7 million through Sep 2025, up 36.45% year-over-year, with the annual reading at $3.7 million for FY2024, 8.58% up from the prior year.
  • Total Current Liabilities for Q3 2025 was $6.7 million at Inhibikase Therapeutics, down from $8.8 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $8.8 million in Q2 2025, with the low at $1.9 million in Q2 2021.
  • Average Total Current Liabilities over 5 years is $4.2 million, with a median of $3.7 million recorded in 2022.
  • The sharpest move saw Total Current Liabilities decreased 14.67% in 2023, then surged 137.53% in 2025.
  • Over 5 years, Total Current Liabilities stood at $4.1 million in 2021, then decreased by 8.85% to $3.7 million in 2022, then dropped by 6.95% to $3.4 million in 2023, then increased by 8.58% to $3.7 million in 2024, then surged by 79.35% to $6.7 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $6.7 million, $8.8 million, and $8.6 million for Q3 2025, Q2 2025, and Q1 2025 respectively.